Cambridge Scientists Discover Sustainable "Anti-Friedel-Crafts" Reaction to Transform Late-Stage Pharmaceutical Manufacturing Processes

Cambridge scientists find a way to use LED light instead of toxic chemicals for drug manufacturing, enabling faster and more sustainable medicine development.

By: AXL Media

Published: Mar 12, 2026, 7:58 AM EDT

Source: Information for this report was sourced from St. John's College, University of Cambridge

The Serendipitous Discovery of a New Chemical Path

A routine laboratory setback at the University of Cambridge has resulted in a significant breakthrough for the pharmaceutical industry, offering a cleaner method for creating fundamental chemical bonds. While conducting a control test for a photocatalyst, researcher David Vahey observed that a reaction proceeded more efficiently without the intended catalyst, leading to the identification of a self-sustaining chain process. Published in Nature Synthesis, this discovery introduces what the team calls an "anti-Friedel-Crafts" reaction. This new pathway allows for the formation of carbon-carbon bonds—the structural backbone of most medicines—under mild conditions that were previously thought impossible to achieve without harsh reagents.

Overcoming the Constraints of Traditional Synthesis

For decades, medicinal chemistry has relied on the classic Friedel-Crafts reaction, a process that typically requires strong acids or heavy metal catalysts and extreme temperatures. These aggressive conditions often limit the reaction to the very beginning of a drug's manufacturing sequence, as the sensitive structures of a nearly finished medicine would be destroyed by such treatment. According to the research team at St. John’s College, the new light-powered approach completely reverses this traditional workflow. By utilizing an LED lamp at ambient temperature, scientists can now perform "late-stage optimization," making precise adjustments to a molecule that is already mostly assembled, rather than rebuilding it from the ground up.

Precision Engineering Through High Functional-Group Tolerance

One of the most valuable aspects of the Cambridge discovery is its high level of selectivity, which chemists refer to as functional-group tolerance. This means the light-triggered reaction can target and alter a specific part of a complex drug molecule without disturbing other sensitive regions. This precision is vital in drug development, where a minor structural change can radically alter how a medicine interacts with the human body or minimize its side effects. David Vahey noted that this tool allows researchers to test subtle modifications in days rather than months, effectively opening up "chemical space" that was previously deemed too difficult or volatile to access.